LLY · News · 20260906N

Product / Drug Pipeline Progress - Lp(a)

ELI LILLY & Co · 2026-09-06 · Importance 5 · Surprise 24

Novartis and Ionis Pharmaceuticals’ Phase 3 pelacarsen trial failed to reduce heart attacks and strokes, despite lowering lipoprotein(a) levels. The result raises uncertainty for the emerging Lp(a)-targeted cardiovascular drug class and could affect development expectations for Eli Lilly’s comparable therapies. Detailed trial results are expected at an upcoming medical meeting, which may influence Lilly’s cardiovascular pipeline strategy and investment outlook.

Key facts

• Pelacarsen failed to reduce the risk of major cardiovascular events in a large Phase 3 clinical trial despite successfully lowering levels of lipoprotein(a) (Lp(a)), an outcome that "raises significant questions for other companies, such as Eli Lilly ... that are developing similar therapies." source